ABVC 8-K
Abvc Biopharma, Inc. (ABVC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number including area
code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into Material Definitive Agreements
On May 23, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“Oncox”), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC’s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndrome (the “Licensed Products”), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the “Oncox Agreement”). In consideration thereof, Oncox shall pay ABVC a total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share1) 30 days after entering the Oncox Agreement, with an additional milestone payment of $625,000 in cash after OncoX’s next round of fundraising, of which there can be no guarantee. Oncox may remit cash payments of at least $100,000 towards the licensing fees and deductible from the second milestone payment; ABVC is also entitled to royalties of 5% of Net Sales, as defined in the Oncox Agreement, from the first commercial sale of the Licensed Product in the noted territory, which remains uncertain. Oncox may use its revenue to fund the licensing fees. Oncox entered into the same agreement with ABVC’s affiliate, Biolite, Inc.
The foregoing description of the agreements is not complete and is qualified in its entirety by reference to the full text of the agreements, copies of which are attached as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.
Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described herein. Such disclosure does not constitute an offer to sell, or the solicitation of an offer to buy nor shall there be any sales of the Company’s securities in any state in which such an offer, solicitation or sale would be unlawful. The securities mentioned herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws.
Item 9.01 Financial Statement and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 10.1 | Definitive License Agreement between the Company and OncoX BioPharma, Inc. May 23, 2024 | |
| 10.2 | Definitive License Agreement between Biolite, Inc. and OncoX BioPharma, Inc. dated May 23, 2024 | |
| 99.1 | Press Release | |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL |
| 1 | Price was determined through private negotiations between the parties; no third party valuation was completed. |
1
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABVC BioPharma, Inc. | ||
| May 24, 2024 | By: | /s/ Uttam Patil |
| Uttam Patil | ||
| Chief Executive Officer | ||
2
Exhibit 10.1
Definitive Licensing Agreement
This Definitive Licensing Agreement (“Agreement”) is entered into this May 23, 2024 (the “Effective Date”) by and between:
| (1) | ABVC BioPharma, Inc., a company registered in Nevada. (“ABVC”); and |
| (2) | OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and |
ABVC and ONCOX shall be referred to individually as a “Party” and collectively as the “Parties”.
WHEREAS, the parties have agreed to the Key Terms (see Exhibit A) as outlined in the Term Sheet, and now formalize their understanding in this Definitive Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties agree as follows:
1. Upon signing this Definitive Agreement, ONCOX shall have the exclusive right, until the expiration of this agreement, to negotiate and execute a definitive licensing agreement for the licensed products with ABVC.
2. ONCOX has the right to team with partner(s) or transfer the right to a third party to negotiate and execute a definitive licensing agreement for the licensed products with ABVC.
3. ONCOX has satisfactorily completed a due diligence investigation of the Licensed Product.
4. ABVC and its Representatives shall deal exclusively with ONCOX with respect to any licensing in the same scope or similar arrangement surrounding the Licensed Product.
IN WITNESS WHEREOF, the parties hereto have executed this Definitive Agreement as of the Effective Date.
[Signature Page]
| ABVC BioPharma, Inc. | OncoX BioPharma, Inc. | |||
| Authorized Signature/Seal | Authorized Signature/Seal | |||
| Name： | Uttam Yashwant Patil | Name： | Yen Wen Pin | |
| Title: | Title： | |||
| CEO | CEO | |||
2
Exhibit A
| LICENSEE | OncoX BioPharma, Inc. (“ONCOX”) |
| LICENSOR | ABVC BioPharma, Inc. (“ABVC”) and its affiliates |
| THIRD PARTY | “Third Party” means a person or entity other than ONCOX or ABVC or their respective affiliates. |
| EFFECTIVE DATE | The effective dates of Definitive Agreement related to the Licensed Product that would be the result of Parties’ discussions |
|
LICENSED PRODUCT
|
ABVC’s BLEX 404, single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndromes (MDS) |
| TERRITORY | 50% of the Worldwide Markets |
| GOVERNING LAW | Laws of the United States |
| FIELD OF USE | Myelodysplastic Syndromes (MDS) |
|
RIGHTS GRANTED
|
ABVC shall grant to ONCOX an exclusive right within the Territory license to develop and commercialize the Licensed Product in the Territory within the Field of Use. |
|
RESPONSIBILITIES & OBLIGATIONS
|
ABVC will be responsible for conducting the clinical development of the Licensed Product outside Territory and communicating the results as part of the Product Transfer (PT), which includes delivering the Licensed Product sufficient to support the clinical studies in Territory, delivering associated documents, manufacturing protocols, QC protocols, to enable ONCOX to develop and commercialize the Licensed Product in Territory.
ABVC will be responsible to secure the supply of the Licensed Product to ONCOX in the Territory with an agreed price and quantity while A will secure the purchase of the Licensed Products from ABVC in the Territory with committed volume.
ONCOX shall be responsible for completing regulatory filing of IND in the Territory.
ABVC will be responsible for providing the Licensed Product to ONCOX at cost, to support clinical development in the Field of Use in the Territory.
ONCOX will be responsible for further development and commercialization of the Licensed Product in the Field of Use in the Territory, including any clinical development, regulatory affairs (including regulatory filings and approvals), and commercialization of the Licensed Product.
As part of this license, ONCOX will grant ABVC a perpetual, royalty-free right to use and reference any development, regulatory, and market data associated with the Licensed Product in ONCOX’s control. |
|
EXCLUSIVITY/ NON-COMPETE |
During the collaboration, neither Parties nor its affiliates will work on the development of or commercialize in the Territory any products containing Maitake Mushroom as the sole active ingredient or in combination with one or more other active ingredients other than with respect to any other product or usage for which the same parties have previously agreed or will agree to work on together or without a specific mutually agreed to written plan for depression indication. |
3
| TECHNOLOGY SHARING | After the Effective Date, and at a time to be agreed upon by ONCOX and ABVC in the Definitive Agreement, ABVC would transfer to ONCOX in English that data related to any Licensed Products in ABVC’s possession and control that is required by regulatory authorities for opening an IND, NDA. |
|
INTELLECTUAL PROPERTY RIGHTS
|
Intellectual Property means any patent, copyright, trade secret, trademark or other proprietary right；including all their applications , registrations, renewals and extensions.
Each Party or its Affiliates owns all rights, title and interest of the Intellectual Property developed or controlled by itself and will be responsible for filing and maintaining the Intellectual Property in the Territory at its own cost.
Each Party warrants it does not and will not infringe, violate or misappropriate any trademark, patent, copyright, industrial design, trade secret or any other intellectual property or proprietary right of any Third Party.
No right, title or interest is granted to the other Party in the Definitive Agreement, whether expressly or by implication, to any technology or Intellectual Property rights owned by a Party other than pursuant to the terms of the Definitive Agreement.
Each Party will retain an unconditional and unlimited right of access, inclusion, citation, electronic or photo copy, and regulatory cross reference, without limitation, to any and all regulatory, technical, and scientific documentations, and any and all communications with any and all regulatory authorities in the other Party’s Territory for all matters related to each Licensed Product during the License Term. |
| MILESTONE & ROYALTY PAYMENTS | See Exhibit B. |
|
TAX
|
Payments to Licensor as detailed in Exhibit B are likely considered Licensor’s income generated in Territory. Licensor is responsible for income tax, value-added tax, and other related fees levied by Territory government authorities on these payments. If and to the extent that provision is made in law or regulation of Territory for withholding of taxes with respect to any such payment, Licensee shall pay such taxes on behalf of Licensor and provide Licensor with original receipt of such tax payments or withholding. |
| NET SALES |
“Net Sales” means the total amount of invoices issued by the Licensee for selling the Product of each pack size in the Territory to the Third Parties responsible for distribution / logistics, minus the amount of allowable deduction items related to the Product actually provided to non-affiliates as follows:
a) sales value added tax
b) allowance, discount or rebate for rejection, defect, recall, return, retroactive price reduction
Net Sales shall be accounted in accordance with arm-length principles, industry standards and practices of the Territory, covering all sales of the Product to the Field of Use in the Territory. Any allowance, discount or rebate for any Third Party sales and marketing activities shall not be deducted from the Net Sales calculation.
Licensee shall allow Licensor to appoint a Third Party independent auditor to audit the financial accounts of Licensee or its affiliates to confirm the reasonableness and accuracy of the Net Sales calculation of the Product each year during the License Term. |
| LICENSE TERMS | The term of licensing for the Licensed Product in the Territory is 20 years. |
|
MANUFACTURING
|
Both Parties desire Licensee is responsible for the Licensed Product API manufacturing under CMO model as global primary supplier. Both Parties agree further study and analysis are to be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.
Manufacturing of Licensed Product finished product is subject to negotiation by both Parties. |
4
Exhibit B
All payments below are pre-tax total payments in USD.
| Milestones | Timeline | Payment to ABVC |
| Upfront | Due 30 days after the signature of the Investment Agreement |
$6,250,000 (or 1,250,000 shares of ONCOX at $5/share) |
| A cash payment of $100,000 and above at any time will then be deducted from the second milestone payment. | ||
|
Completion Of Fundraising |
Due 30 days upon completion of next round fundraising | US $625,000 |
| Total Licensing Fee | $6,875,000 | |
| Royalties |
5% of annual Net Sales, accumulated to a total of US$6,250,000 | |
Royalties shall be payable quarterly on annual Net Sales of the Licensed Product from the first commercial sale of a Licensed Product in the Territory to the end of License Terms.
5
Exhibit 10.2
Definitive Licensing Agreement
This Definitive Licensing Agreement (“Agreement”) is entered into this May 23, 2024 (the “Effective Date”) by and between:
| (1) | BIOLITE, INC., a company registered in Taiwan. (“BIOLITE”); and |
| (2) | OncoX BioPharma, Inc. (“ONCOX”), a company registered in the British Virgin Islands.; and |
BIOLITE and ONCOX shall be referred to individually as a “Party” and collectively as the “Parties”.
WHEREAS, the parties have agreed to the Key Terms (see Exhibit A) as outlined in the Term Sheet, and now formalize their understanding in this Definitive Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties agree as follows:
1. Upon signing this Definitive Agreement, ONCOX shall have the exclusive right, until the expiration of this agreement, to negotiate and execute a definitive licensing agreement for the licensed products with BIOLITE.
2. ONCOX has the right to team with partner(s) or transfer the right to a third party to negotiate and execute a definitive licensing agreement for the licensed products with BIOLITE.
3. ONCOX has satisfactorily completed a due diligence investigation of the Licensed Product.
4. BIOLITE and its Representatives shall deal exclusively with ONCOX with respect to any licensing in the same scope or similar arrangement surrounding the Licensed Product.
IN WITNESS WHEREOF, the parties hereto have executed this Definitive Agreement as of the Effective Date.
[Signature Page]
BIOLITE, INC. |
OncoX BioPharma, Inc. | |||
| Authorized Signature/Seal | Authorized Signature/Seal | |||
| Name： | Tsung Shann Jiang | Name： | Yen Wen Pin | |
| Title: | Title： | |||
| CEO | CEO | |||
2
Exhibit A
| LICENSEE | OncoX BioPharma, Inc. (“ONCOX”) |
| LICENSOR | BIOLITE, INC. (“BIOLITE”) and its affiliates |
| THIRD PARTY | “Third Party” means a person or entity other than ONCOX or BIOLITE or their respective affiliates. |
| EFFECTIVE DATE | The effective dates of Definitive Agreement related to the Licensed Product that would be the result of Parties’ discussions |
|
LICENSED PRODUCT
|
BIOLITE’s BLEX 404, single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Myelodysplastic Syndromes (MDS) |
| TERRITORY | 50% of the Worldwide Markets |
| GOVERNING LAW | Laws of the United States |
| FIELD OF USE | Myelodysplastic Syndromes (MDS) |
|
RIGHTS GRANTED
|
BIOLITE shall grant to ONCOX an exclusive right within the Territory license to develop and commercialize the Licensed Product in the Territory within the Field of Use. |
|
RESPONSIBILITIES & OBLIGATIONS
|
BIOLITE will be responsible for conducting the clinical development of the Licensed Product outside Territory and communicating the results as part of the Product Transfer (PT), which includes delivering the Licensed Product sufficient to support the clinical studies in Territory, delivering associated documents, manufacturing protocols, QC protocols, to enable ONCOX to develop and commercialize the Licensed Product in Territory.
BIOLITE will be responsible to secure the supply of the Licensed Product to ONCOX in the Territory with an agreed price and quantity while A will secure the purchase of the Licensed Products from BIOLITE in the Territory with committed volume.
ONCOX shall be responsible for completing regulatory filing of IND in the Territory.
BIOLITE will be responsible for providing the Licensed Product to ONCOX at cost, to support clinical development in the Field of Use in the Territory.
ONCOX will be responsible for further development and commercialization of the Licensed Product in the Field of Use in the Territory, including any clinical development, regulatory affairs (including regulatory filings and approvals), and commercialization of the Licensed Product.
As part of this license, ONCOX will grant BIOLITE a perpetual, royalty-free right to use and reference any development, regulatory, and market data associated with the Licensed Product in ONCOX’s control. |
|
EXCLUSIVITY/ NON-COMPETE |
During the collaboration, neither Parties nor its affiliates will work on the development of or commercialize in the Territory any products containing Maitake Mushroom as the sole active ingredient or in combination with one or more other active ingredients other than with respect to any other product or usage for which the same parties have previously agreed or will agree to work on together or without a specific mutually agreed to written plan for depression indication. |
3
| TECHNOLOGY SHARING | After the Effective Date, and at a time to be agreed upon by ONCOX and BIOLITE in the Definitive Agreement, BIOLITE would transfer to ONCOX in English that data related to any Licensed Products in BIOLITE’s possession and control that is required by regulatory authorities for opening an IND, NDA. |
|
INTELLECTUAL PROPERTY RIGHTS
|
Intellectual Property means any patent, copyright, trade secret, trademark or other proprietary right；including all their applications , registrations, renewals and extensions.
Each Party or its Affiliates owns all rights, title and interest of the Intellectual Property developed or controlled by itself and will be responsible for filing and maintaining the Intellectual Property in the Territory at its own cost.
Each Party warrants it does not and will not infringe, violate or misappropriate any trademark, patent, copyright, industrial design, trade secret or any other intellectual property or proprietary right of any Third Party.
No right, title or interest is granted to the other Party in the Definitive Agreement, whether expressly or by implication, to any technology or Intellectual Property rights owned by a Party other than pursuant to the terms of the Definitive Agreement.
Each Party will retain an unconditional and unlimited right of access, inclusion, citation, electronic or photo copy, and regulatory cross reference, without limitation, to any and all regulatory, technical, and scientific documentations, and any and all communications with any and all regulatory authorities in the other Party’s Territory for all matters related to each Licensed Product during the License Term. |
| MILESTONE & ROYALTY PAYMENTS | See Exhibit B. |
|
TAX
|
Payments to Licensor as detailed in Exhibit B are likely considered Licensor’s income generated in Territory. Licensor is responsible for income tax, value-added tax, and other related fees levied by Territory government authorities on these payments. If and to the extent that provision is made in law or regulation of Territory for withholding of taxes with respect to any such payment, Licensee shall pay such taxes on behalf of Licensor and provide Licensor with original receipt of such tax payments or withholding. |
| NET SALES |
“Net Sales” means the total amount of invoices issued by the Licensee for selling the Product of each pack size in the Territory to the Third Parties responsible for distribution / logistics, minus the amount of allowable deduction items related to the Product actually provided to non-affiliates as follows:
a) sales value added tax
b) allowance, discount or rebate for rejection, defect, recall, return, retroactive price reduction
Net Sales shall be accounted in accordance with arm-length principles, industry standards and practices of the Territory, covering all sales of the Product to the Field of Use in the Territory. Any allowance, discount or rebate for any Third Party sales and marketing activities shall not be deducted from the Net Sales calculation.
Licensee shall allow Licensor to appoint a Third Party independent auditor to audit the financial accounts of Licensee or its affiliates to confirm the reasonableness and accuracy of the Net Sales calculation of the Product each year during the License Term. |
| LICENSE TERMS | The term of licensing for the Licensed Product in the Territory is 20 years. |
|
MANUFACTURING
|
Both Parties desire Licensee is responsible for the Licensed Product API manufacturing under CMO model as global primary supplier. Both Parties agree further study and analysis are to be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement. Manufacturing of Licensed Product finished product is subject to negotiation by both Parties. |
4
Exhibit B
All payments below are pre-tax total payments in USD.
| Milestones | Timeline | Payment to BIOLITE |
| Upfront | Due 30 days after the signature of the Investment Agreement |
$6,250,000 (or 1,250,000 shares of ONCOX at $5/share) |
| A cash payment of $100,000 and above at any time will then be deducted from the second milestone payment. | ||
|
Completion Of Fundraising |
Due 30 days upon completion of next round fundraising | US $625,000 |
| Total Licensing Fee | $6,875,000 | |
| Royalties |
5% of annual Net Sales, accumulated to a total of US$6,250,000 | |
Royalties shall be payable quarterly on annual Net Sales of the Licensed Product from the first commercial sale of a Licensed Product in the Territory to the end of License Terms.
5
Exhibit 99.1
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
Fremont, CA (May 24, 2024) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today a significant step in the fight against Myelodysplastic Syndrome. The Company and its subsidiary BioLite, Inc. have entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands, to collaborate on a combination therapy. We believe this therapy holds the potential to revolutionize Myelodysplastic Syndrome treatment and significantly improve patient outcomes. ABVC and its subsidiary are eligible to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional aggregate milestone payment of $1,250,000 in cash after OncoX’s next round of fundraising, of which there can be no guarantee. OncoX may remit partial cash payments of at least $100,000 to the licensing fees, which would be deductible from the second milestone payment. ABVC and its subsidiary are also entitled to receive royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product, which remains uncertain. There is no guarantee that ABVC or its subsidiary will receive any of the fees listed.
The United States Food & Drug Administration (US FDA) has granted its approval to four INDs, a testament to the safety and efficacy of our investigational new drugs. These include ABV-1501 (IND 129575) for Triple Negative Breast Cancer (TNBC), ABV-1519 (IND 161602) for Non-Small Cell Lung Cancer (NSCLC), ABV-1702 (IND 131300) for Myelodysplastic Syndrome (MDS), and ABV-1703 (IND 136309) for Pancreatic Cancer Therapy. The Investigational New Drug (IND) application for ABV-1703 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy. The active ingredient of BLEX 404 is the β-glucan extracted from Grifola frondosa (maitake mushrooms), an edible fungus with high medical and commercial values in Asia; it contains various bioactive constituents such as polysaccharides, pyrrole alkaloids, ergosterol, etc., and has been widely served as functional foods for a long time in daily life.1
Myelodysplastic Syndromes, a group of diverse bone marrow disorders characterized by ineffective blood cell production, have posed substantial challenges to conventional treatment methodologies.2 MDS and its treatments can significantly impact patients’ quality of life due to symptoms such as fatigue, anemia, and infection risk. More effective supportive care strategies and symptom management approaches are needed to enhance patients’ well-being and functional status.3 In vitro results have proven that β-glucan of MD-fraction, a key ingredient of BLEX 404, enhances bone marrow colony formation and reduces chemotherapy toxicity.4
| 1 | https://www.sciencedirect.com/science/article/abs/pii/S0960852407001083?via%3Dihub |
| 2 | https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia |
| 3 | https://pubmed.ncbi.nlm.nih.gov/34045662/ |
| 4 | https://www.sciencedirect.com/science/article/abs/pii/S1567576903002765#:~:text=Maitake%20beta%2Dglucan%20MD%2Dfraction,doxorubicin%20toxicity%20in%20vitro%20%2D%20ScienceDirect |
“This landmark collaboration aims to revolutionize MDS treatment by developing a novel combination therapy. We expect this innovative combination therapy, the result of extensive research and development efforts, to significantly improve patient outcomes by addressing the underlying mechanisms of MDS more comprehensively than current treatments allow. By leveraging synergistic effects between multiple therapeutic agents, this approach aims to enhance efficacy while minimizing adverse effects, offering new hope to patients and healthcare professionals alike, said Dr. Uttam Patil, ABVC’s Chief Executive Officer. He added, “Through this collaboration, we aim to redefine the standard of care for MDS patients, empowering them with more effective and personalized treatment options.”
“We are thrilled to announce this definitive agreement with ABVC, which marks a pivotal moment in our ongoing commitment to advancing the field of oncology and hematological disorders,” said Wen-Pin Yen, CEO of OncoX. He added, “OncoX shares this enthusiasm for the collaboration’s potential impact and is excited to combine the scientific expertise of ABVC’s innovative approach to develop a therapy that can potentially transform the lives of MDS patients. This partnership represents a significant step forward in our shared mission to address unmet medical needs and improve patient outcomes.”
Under the terms of the agreement, ABVC grants OncoX exclusive rights for one of ABVC’s four products in its Oncology pipeline to develop, manufacture, and commercialize BLEX 404, a promising therapeutic agent for the treatment of Myelodysplastic Syndromes. The license has a term of 20 years within a specified territory.
Management believes the Company’s product pipeline has excellent market potential. The global cancer therapeutics market is expected to be worth around US$393.61 billion by 2032, up from US$164 billion in 2022, growing at a CAGR of 9.20% from 2023 to 2032.5 Myelodysplastic Syndrome (MDS) Treatment market is projected to reach US$ 6102.7 million in 2029, increasing from US$ 3270 million in 2022, with the CAGR of 9.2% during the period of 2023 to 2029.6
For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. ABVC urges its shareholders to sign up on the Company’s website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.
| 5 | https://www.precedenceresearch.com/cancer-therapeutics-market |
| 6 | https://www.linkedin.com/pulse/myelodysplastic-syndrome-mds-treatment-market-insights-qw6uc/ |
2
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Leeds Chow
Email: [email protected]
3